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Summary
Background.  —  Catheter  ablation  is  widely  used  to  treat  symptomatic  atrial  ﬁbrillation  (AF)
refractory to  drug  therapy;  and  can  be  facilitated  by  a  number  of  different  techniques.
Aims. —  To  evaluate  our  performance  as  a  new  centre  for  AF  ablation  and  to  evaluate  the
efﬁcacy of  different  AF  ablation  techniques.
Methods.  —  We  employed  three  techniques  in  AF  ablations;  the  three-dimensional  (3D)  mapping
approaches  (CARTO® or  Ensite  NavX®)  or  multielectrode  catheter  duty-cycled  radiofrequency
ablation (pulmonary  vein  ablation  catheter  [PVAC®]).  The  immediate  restoration  of  sinus  rhythm
was considered  as  acute  success;  while  success  at  6  months  was  determined  by  the  maintenance
of sinus  rhythm  on  Holter  monitoring.
008  and  March  2010,  109  patients  underwent  AF  ablations  (meanResults.  —  Between  March  2
age: 58  years;  72%  male).  Six-month  success  rates  did  not  differ  signiﬁcantly  between  CARTO
and NavX  (40%  vs  38%;  P  =  0.81),  but  the  PVAC  group  achieved  greater  success  than  the  two  3D-
mapping groups  combined  (68%  vs  39%;  P  =  0.004).  Paroxysmal  AF  patients  demonstrated  greater
Abbreviations: 3D, Three-dimensional; AF, Atrial ﬁbrillation; AFA, Atrial ﬁbrillation ablation; ECG, Electrocardiogram; LA, Left atrium;
LVEF, Left ventricular ejection fraction; PV, Pulmonary veins; PVAC, Pulmonary vein ablation catheter; PVI, Pulmonary vein isolation; RF,
Radiofrequency; WACA, Wide area circumferential ablation.
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6-month  success  than  persistent  AF  patients  (P  =  0.005);  and  although  the  ratio  of  paroxysmal  to
persistent  AF  patients  was  slightly  higher  among  the  PVAC  group,  logistic  regression  conﬁrmed
PVAC and  paroxysmal  AF  as  predictors  of  success.  Single-procedure  success  at  6  months  was
48%. Including  redo-ablations,  some  performed  beyond  the  study  period,  our  overall  success
rate at  6  months  was  65%.  Four  patients  experienced  complications,  but  there  were  no  deaths.
Conclusion.  —  Despite  being  a  new  centre  with  relative  inexperience,  we  achieved  success  rates
comparable  to  those  of  established  tertiary  centres.  PVAC  performed  signiﬁcantly  better  than
the two  3D-mapping  approaches.
© 2011  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé  Aﬁn  d’évaluer  notre  performance  comme  un  nouveau  centre  pour  la  ﬁbrillation
auriculaire (FA)  dans  trois  techniques  d’ablation,  les  approches  cartographie  en  trois  dimensions
(3D) utilisant  CARTO® ou  NavX® et  l’ablation  par  radiofréquence  multiélectrodes  décapolaire
circulaire  à  l’aide  du  cathéter  d’ablation  des  veines  pulmonaires  (PVAC®).
Méthodes.  —  Au  cours  des  24  premiers  mois  de  mars  2008,  nous  avons  réalisé  109  cas  d’ablation
de la  FA.  La  restauration  immédiate  du  rythme  sinusal  par  ablation  a  été  considéré  comme  un
succès instantané.  La  réussite  à  six  mois  a  été  déterminée  par  le  maintien  du  rythme  sinusal
au monitoring  du  Holter.
Résultats.  —  L’âge  moyen  de  notre  cohorte  était  de  58  ans.  Le  taux  de  réussite  à  six  mois  ne
différaient  pas  signiﬁcativement  entre  les  CARTO® et  NavX® (40  %  vs  38  %,  p  =  0,81)  mais  le
groupe PVAC  a  connu  plus  de  succès  que  les  deux  combinés  groupes  en  3D  cartographie  (68  %  vs
39 %,  p  =  0,004).  Les  patients  FA  paroxystique  (FAP)  ont  démontré  une  réussite  plus  grande  de
patients  atteints  de  FA  tenace  à  six  mois  (p  =  0,005).  La  proportion  des  patients  paroxystique  et
de FA  tenace  n’était  pas  signiﬁcativement  différente  entre  les  groupes  de  cartographie  3D  et
PVAC. La  régression  logistique  a  conﬁrmé  FAP  et  PVAC  comme  prédicteurs  de  succès.  Le  succès
de une  seule  procédure  à  six  mois  était  de  48  %.  Y  compris  les  ablations  refait  au-delà  de  la
période d’étude,  notre  taux  de  réussite  global  à  six  mois  était  de  65  %.  Nous  avons  eu  quatre
complications,  mais  aucun  décès  liés  à  l’arythmie.
Conclusions.  — En  dépit  d’un  nouveau  centre  et  de  l’inexpérience  relative,  nous  avons  atteint
les taux  de  succès  comparables  à  ceux  des  centres  de  soins  tertiaires  établis.  PVAC  fait
signiﬁcativement  meilleurs  que  les  deux  approches  de  cartographie  en  3D.  Nous  recomman-
dons donc  l’ouverture  de  plusieurs  installations  d’ablation  de  la  FA  et  l’adoption  de  PVAC  dans
ces centres.
©  2011  Elsevier  Masson  SAS.  Tous  droits  réservés.
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Patients  underwent  ablation  using  CARTO,  NavX,  or  PVAC.
Techniques  were  selected  on  a  random  basis  in  our  cohort.Background
Catheter  ablation  of  atrial  ﬁbrillation  (AF)  has  been  widely
used  in  the  treatment  of  symptomatic  AF,  as  well  as  AF
refractory  to  drug  therapy  or  cardioversion  [1].  AF  abla-
tion  (AFA)  involves  the  isolation  of  triggers  within  pulmonary
veins  (PVs)  using  radiofrequency  (RF)  energy  [2].  To  facili-
tate  this,  CARTO  (Biosense  Webster,  Diamond  Bar,  CA,  USA)
uses  magnetic  ﬁelds  to  construct  a  three-dimensional  (3D)
geometry  of  the  left  atrium  (LA),  while  Ensite  NavX  (St  Jude
Medical,  St  Paul,  MN,  USA)  uses  electrical  ﬁelds  to  gen-
erate  3D  maps.  Pulmonary  vein  ablation  catheter  (PVAC)
(Medtronic,  Ablation  Frontiers,  Carlsbad,  CA,  USA)  simpliﬁes
PV  isolation  procedures  by  using  a  multielectrode  catheter
capable  of  circular  mapping  and  duty-cycled  RF  energy
delivery  without  3D  guidance.
The  aim  of  this  retrospective  study  was  to  compare  the
efﬁcacy  of  CARTO  and  NavX  with  that  of  PVAC,  and  to  eval-
uate  the  performance  of  our  new  institution  in  a  6-month
follow-up. Tethods
atients
ur  institution  started  performing  AFAs  in  March  2008,
ndertaken  by  two  operators.  Patients  included  those  with
aroxysmal  AF  (self-terminating  AF  lasting  <  7  days)  or  per-
istent  AF  (lasting  for  >  7  days  but  <  1  year)  [3].
Transoesophageal  echocardiogram  was  routinely  per-
ormed  prior  to  ablation  procedures  to  rule  out  atrial
hrombi.  Warfarin  was  discontinued  5  days  prior  to  the
rocedures  and  was  replaced  with  low-molecular-weight
eparin.  This  study  formed  part  of  a  service  evaluation  of
ur  new  institution.
blation procedureshe  ablation  procedures  were  performed  under  conscious
3s
t
w
t
p
w
i
f
M
U
w
l
L
A
b
v
t
o
s
D
i
t
m
l
c
P
t
w
t
c
o
n
c
l
p
P
l
g
u
t
a
a
u
n
w
t
P
A
f
w
w
i
w
b
p
u
E
m
w
d
t
c
t
S
C
i
v
c
e
l
i
p
R
P
I
T
b
w
d
T
m
a
d
i
2
5
N
n
g
w
T
i
w
(
ﬂ
r
s
2
1
s
P
r
c
T98  
edation  using  diazepam  and  pethidine  or  general  anaes-
hesia.  Surface  and  intracardiac  electrocardiograms  (ECGs)
ere  continuously  monitored  and  recorded.  In  all  three
echniques,  a  steerable  multipolar  electrode  catheter  was
ositioned  in  the  coronary  sinus  for  pacing  and  recording.
LA  access  was  gained  through  a  transseptal  puncture
ith  Brockenbrough  (St.  Jude  Medical)  or  Endrys  (Cook  Med-
cal,  Bloomington,  IN,  USA)  needle,  or  through  a  patent
oramen  ovale  when  present.  An  SL1  (St.  Jude  Medical),
ullins  (Cook  Medical),  or  Channel  (Bard,  Covington,  GA,
SA)  sheath  was  then  introduced  into  the  LA  and  infused
ith  0.9%  saline.  In  the  3D-mapping  approaches,  a  multipo-
ar  mapping  catheter  (Orbiter  [Bard],  Optima  [St.  Jude],  or
asso  [Biosense  Webster])  was  passed  through  this  sheath.
n  initial  bolus  of  10,000  units  of  heparin  was  given,  followed
y  2500—5000  units  of  additional  boluses  to  maintain  an  acti-
ated  clotting  time  of  300—400  seconds.  Activated  clotting
imes  were  determined  every  30  minutes.
CARTO-  and  NavX-guided  ablations  were  done  with  30  W
f  RF  energy  delivered  through  an  ablation  catheter  (Cel-
ius  or  Navistar  Thermocool  [Biosense  Webster]  or  Cool  Path
uo  [St.  Jude  Medical])  advanced  into  the  LA  through  the
nitial  puncture  whenever  possible.  Otherwise,  a  second
ransseptal  puncture  was  performed.  The  catheter  tip  was
aintained  <  48 ◦C  with  irrigated  saline.  Pulmonary  vein  iso-
ation  (PVI)  was  the  primary  goal  in  all  cases.  Wide  area
ircumferential  ablation  (WACA)  was  performed  around  the
V  antrum,  proximal  to  PV  ostia,  in  all  patients.  No  abla-
ions  were  done  within  or  distal  to  PV  ostia.  Successful  PVI
as  conﬁrmed  by  circular  mapping  catheters  positioned  at
he  PV  ostia.  Linear  ablations  in  the  forms  of  roof,  ﬂoor,  and
oronary  sinus  lines  were  done  in  addition  to  PVI  in  cases
f  persistent  AF  [4,5]. Burns  were  performed  in  the  coro-
ary  sinus  and  LA  surface  of  the  coronary  sinus  until  deﬁnite
hange  in  coronary  sinus  activation  suggested  electrical  iso-
ation.  Other  linear  burns  were  assessed  by  juxtaposed  atrial
acing  and  presence  of  homogenous  line  of  split  potentials.
In  PVAC  ablations,  after  access  into  LA  was  gained,  the
VAC  was  positioned  at  the  antrum  of  each  PV  to  record
ocal  electrical  activity.  RF  energy  was  applied  with  a  tar-
et  temperature  of  60 ◦C  and  4/1  ratio  between  bipolar  and
nipolar  energy.  Multiple  applications  of  RF  were  delivered
o  achieve  antral  isolation.  Then,  the  PVAC  was  used  to  map
ll  PV  ostia.  If  PVs  appeared  to  be  incompletely  isolated,
dditional  RF  applications  were  delivered  using  the  PVAC
ntil  PVs  were  completely  disconnected,  based  on  PVAC  sig-
als  and  differential  pacing  manoeuvres.  DC  cardioversion
as  performed  if  sinus  rhythm  was  not  restored  following
he  ablations.
ost-ablation and follow-up
fter  ablation,  patients  remained  in  hospital  for  ≥  24  hours
or  telemetry  monitoring.  Patients  were  anti-coagulated
ith  warfarin  for  ≥  3  months.  Low-molecular-weight  heparin
as  administered  until  a  therapeutic  international  normal-
zed  ratio  >  2  was  achieved.  A  transthoracic  echocardiogram
as  performed  the  day  after  the  procedure  in  all  cases.  A
lanking  period  of  3  months  was  employed  in  this  study  as
er  international  consensus  [1].  All  patients  were  followed
p  in  the  outpatient  clinic  at  3,  6,  and  12  months.  A  12-lead
P
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CG  was  recorded  at  each  visit;  and  24—48  hours  of  Holter
onitoring  was  performed  at  each  follow-up  for  all  patients.
The  successful  restoration  of  sinus  rhythm  after  ablations
as  considered  as  acute  success.  Success  on  follow-up  was
etermined  by  the  absence  of  symptoms  and  a  lack  of  sus-
ained  AF  of  >  30  seconds  on  Holter  monitoring.  Data  were
ollected  from  TOMCAT  (Philips,  Netherlands)  and  local  elec-
ronic  patient  records.
tatistical analyses
ontinuous  data  are  presented  as  mean  ±  SD,  and  compar-
sons  were  performed  with  Student’s  t  test.  Categorical
ariables  are  expressed  as  frequencies  and  percentages,  and
omparisons  were  performed  with  2 analyses  or  Fisher’s
xact  test.  Multivariable  analyses  were  performed  with
ogistic  regression.  All  P  values  are  two-sided  and  P  <  0.05
ndicates  statistical  signiﬁcance.  Statistical  analyses  were
erformed  using  SPSS  (SPSS  Inc,  Chicago,  IL,  USA).
esults
atient characteristics
n  the  24  months  from  March  2008,  we  performed  117  AFAs.
wo  cases  using  cryoballoon  (Arctic  Front,  Cryocath,  Que-
ec,  Canada)  were  excluded  from  this  study.  Six  patients
ho  had  incomplete  procedures  due  to  vascular  access
ifﬁculties  such  as  femoral  stenoses  were  also  excluded.
herefore,  only  109  patients  (mean  age  57.8  ±  10  years;  72%
ale)  who  received  AFAs  during  the  study  period  were
nalysed.  All  patients  were  symptomatic  and  refractory  to
rug  treatment  prior  to  ablation.  Echocardiographic  record-
ngs  demonstrated  a  mean  LA  size  of  41.6  ±  7.3  mm  (range
5—58  mm)  and  left  ventricular  ejection  fraction  (LVEF)  of
7.1  ±  7.8%  (range  26—70%).
We  performed  47  ablations  with  CARTO  (43%),  24  with
avX  (22%),  and  38  with  PVAC  (35%).  There  were  no  sig-
iﬁcant  differences  in  baseline  characteristics  between  the
roups  (Table  1).  Our  cohort  was  composed  of  73  patients
ith  paroxysmal  AF  (67%)  and  36  with  persistent  AF  (33%).
he  ratio  of  paroxysmal  to  persistent  AF  patients  was  higher
n  the  PVAC  group  than  in  the  3D-mapping  groups,  but  this
as  not  signiﬁcant  (P  =  0.052;  Table  1).
The  mean  total  procedure  time  was  221  ±  67  minutes
median  218  minutes;  range  60—450  minutes)  and  the  mean
uoroscopy  time  was  62  ±  29  minutes  (median  54  minutes;
ange  18—165  minutes).  PVAC  ablations  were  completed
igniﬁcantly  faster  than  3D-guided  ablations  (168  vs
52  minutes;  P  <  0.0001;  Table  1),  taking  and  average  of
59  minutes  for  paroxysmal  AF  and  206  minutes  for  per-
istent  AF.  As  a  result  of  a  shorter  procedure  time,
VAC  also  demonstrated  a  shorter  duration  of  ﬂuo-
oscopy,  with  an  average  screening  time  of  39  minutes,
ompared  to  >  70  minutes  for  the  3D  systems  (P  <  0.0001;
able  1).redictors of success
e  achieved  a  96%  acute  success  rate  with  CARTO,  100%
ith  NavX,  and  97%  with  PVAC  (P  =  0.42;  Table  2).  Six-month
3D  mapping  and  multielectrode  catheter  AF  ablation  399
Table  1 Baseline  clinical  and  procedural  characteristics.
CARTO  (n  =  47)  NavX  (n  =  24)  3D  mapping
(CARTO  +  NavX)  (n  =  71)
PVAC  (n  =  38)  P  (PVAC  vs  3D
mapping)
Age  (years)  56.2  ±  10.5  62.2  ±  7.7  58.2  ±  10.0  56.9  ±  10.2  0.51
Male  32  (68)  17  (71)  49  (69)  29  (76)  0.42
LA  size  (mm)  40.5  ±  7.5  43.9  ±  6.3  41.5  ±  7.3  42.0  ±  7.5  0.79
LVEF  (%) 58.9  ±  6.4  55.4  ±  6.3  57.9  ±  6.5  55.6  ±  9.8  0.24
AF  type 0.052
Paroxysmal 28  (60) 15  (63) 43  (61) 30  (79)
Persistent 19  (40) 9  (38) 28  (39) 8 (21)
Procedure  time  (min) 246  ±  60 265  ±  60 252  ±  60 168  ±  41 < 0.0001
Fluoroscopy  time  (min) 73  ±  27  79  ±  25  75  ±  26  39  ±  14  <  0.0001
Complications  1  (2)  1  (4)  2  (3)  2  (5)  0.61
Data are mean ± standard deviation or number (%). 3D: three-dimensional; AF: atrial ﬁbrillation; LA: left atrium; LVEF: left ventricular
ejection fraction; PVAC: pulmonary vein ablation catheter.
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csuccess  rates  were  similar  in  the  CARTO  and  NavX  groups
(40%  vs  38%,  P  =  0.81),  therefore,  we  merged  the  CARTO
and  NavX  groups  together  for  comparison  against  PVAC.
At  6  months,  the  PVAC  group  performed  signiﬁcantly  bet-
ter  than  the  3D-mapping  groups  (68%  vs  39%;  P =  0.004;
Table  2).
All  of  our  paroxysmal  AF  cases  achieved  acute  success,
compared  to  only  92%  of  persistent  AF  patients  (P  =  0.03;
Table  2).  Also,  more  patients  with  paroxysmal  AF  than  per-
sistent  AF  remained  in  sinus  rhythm  at  6  months  (59%  vs  31%;
P  =  0.005;  Table  2).  A  subgroup  analysis  was  performed  to
examine  the  inﬂuence  of  different  AF  types  on  the  success
of  each  ablation  technique.  Signiﬁcantly,  more  paroxysmal
AF  patients  in  the  PVAC  group  achieved  6-month  success  than
those  in  the  3D-mapping  group  (73%  vs  49%;  P  =  0.04),  but  the
difference  was  not  signiﬁcant  among  persistent  AF  patients
in  these  groups  (50%  vs  25%;  P  =  0.21)  (Table  2).
Age,  LA  size,  LVEF,  and  gender  did  not  inﬂuence  success
at  6  months;  but  success  attributed  to  paroxysmal  AF  and
PVAC  was  conﬁrmed  by  logistic  regression  (Table  3).
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Table  2  Comparison  of  CARTO  with  NavX  and  3D  mapping  wit
CARTO  vs  NavX
CARTO  (n  =  47)  NavX  (n  =  24)  P  
Acute  success
Paroxysmal  28/28  (100)  15/15  (100)  0.9
Persistent  17/19  (89)  9/9  (100)  0.3
Combined  45/47  (96)  24/24  (100)  0.5
6-month  success
Paroxysmal  16/28  (57)  5/15  (33)  0.1
Persistent  3/19  (16)  4/9  (44)  0.1
Combined 19/47  (40)  9/24  (38)  0.8
Data are number/total (%). 3D: three-dimensional; PVAC: pulmonary veingle-procedure success
ingle-procedure  success  at  6  months  was  48%  (Fig.  1).  For
he  purpose  of  this  analysis,  redo  ablations  outside  the
tudy  period  were  included.  Only  one  patient  received  redo
blation  for  the  second  time,  but  continued  to  remain  in  sus-
ained  AF  at  6  months.  Single-procedure  success  combined
ith  success  following  redo  ablations  yielded  an  overall  suc-
ess  rate  of  65%  at  6  months  (Fig.  1).
omplications
our  patients  (3.7%)  had  serious  complications:  one  peri-
ardial  tamponade  (CARTO);  one  pulmonary  vein  puncture
NavX);  one  pericardial  effusion  (PVAC),  and  one  peripro-
edure  stroke  (PVAC).  The  difference  in  complication  rates
etween  the  3D-mapping  groups  and  PVAC  was  not  sta-
istically  signiﬁcant  (P  =  0.61;  Table  1).  The  patient  who
uffered  from  pulmonary  vein  puncture  developed  self-
imiting  haemoptysis  during  the  procedure.  Subsequent
h  PVAC.
3D  mapping  vs  PVAC
3D  mapping  (n  =  71)  PVAC  (n  =  38)  P
9  43/43  (100)  30/30  (100)  0.99
1  26/28  (93)  7/8  (88)  0.54
5  69/71  (97)  37/38  (97)  0.99
4  21/43  (49)  22/30  (73)  0.04
7  7/28  (25)  4/8  (50)  0.21
1  28/71  (39)  26/38  (68)  0.004
in ablation catheter.
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Table  3  Univariate  and  multivariable  analyses  on  predictors  of  success  at  6  months.
Comparison  or  OR  (95%  CI)  P
Univariate  analyses
Age  (years)  (success  vs  failure)  57.2  vs  58.3  0.540
LA  size  (mm)  (success  vs  failure)  40.9  vs  42.3  0.450
LVEF  (%)  (success  vs  failure)  59.5  vs  57.9  0.530
Male  vs  female 0.891  (0.391—2.03)  0.785
Paroxysmal  vs  persistent  AF 3.26  (1.41—7.53)  0.005
PVAC  vs  3D  mapping 3.32  (1.46—7.58)  0.004
Multivariable  analysis  by  logistic  regression
Paroxysmal  vs  persistent  AF 2.83  (1.18—6.78)  0.020
PVAC  vs  3D  mapping  2.91  (1.24—6.86)  0.014
3D: three-dimensional; AF: atrial ﬁbrillation; CI: conﬁdence interval; LA: left atrium; LVEF: left ventricular ejection fraction; OR: odds
ratio; PVAC: pulmonary vein ablation catheter.
investigation  was  consistent  with  trauma  or  perforation  of
pulmonary  veins.  The  patient  with  periprocedure  stroke
developed  unilateral  weakness.  All  complications  were
managed  conservatively,  apart  from  pericardial  tampon-
ade,  which  was  treated  with  pericardiocentesis.  None  of
these  complications  resulted  in  death,  and  there  were  no
arrhythmia-related  deaths  at  6-month  follow-up.
No  formal  screening  for  PV  stenosis  was  done.  How-
ever,  no  patients  suffered  from  symptoms  consistent  with
PV  stenosis  in  our  follow-up.
Discussion
In  this  study,  the  best  outcomes  at  6  months  were  seen
in  paroxysmal  AF  patients  (versus  those  with  persistent
AF)  and  with  PVAC  (versus  3D  mapping)  ablations.  While
the  slightly  higher  ratio  of  paroxysmal  AF  patients  in  the
PVAC  group  may  have  inﬂuenced  the  success  in  this  group,
we  feel  that  the  success  of  PVAC  in  this  study  is  largely
independent  of  the  type  of  AF.  The  imbalance  in  AF  types
Figure 1. Six-month outcomes on initial and redo ablations.
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petween  the  different  groups  has  been  accounted  for  in
he  multivariable  analysis  (Table  3).  In  a  subgroup  analysis
f  only  paroxysmal  AF  patients,  PVAC  also  performed
igniﬁcantly  better  than  3D  mapping  at  6  months.  PVAC  was
 quicker  procedure  and  the  patients  were  exposed  to  the
east  radiation.  As  a  new  centre  performing  AFAs,  we  were
ble  to  achieve  a  satisfactory  overall  success  rate  of  65%  at
 months,  taking  redo  ablations  into  consideration.
Randomized  clinical  trials  have  demonstrated  56—89%
uccess  with  AFA  at  1  year  [6—10]. Almost  all  trials  enrolled
atients  with  a  mean  age  <  60  years,  the  majority  of  whom
ere  men,  similar  to  the  baseline  characteristics  of  patients
n  our  study.
Single-procedure  efﬁcacy  of  catheter  ablation  has  been
eported  to  be  38—78%  for  paroxysmal  AF  and  22—45%  for
ersistent  AF  [1].  Recurrences  of  AF  after  initial  ablation
sually  require  redo  ablation  in  around  20—40%  of  patients
11].  In  our  study,  30%  of  patients  received  at  least  one  redo
blation.  Our  success  in  multiple  procedures  lied  within  the
ublished  range  of  54—80%  [1].
At  present,  there  is  no  consensus  in  selecting  a  technique
or  AFA.  Sommer  et  al.  (n  =  129)  did  not  ﬁnd  any  signiﬁ-
ant  differences  in  outcomes  and  ﬂuoroscopy  times  between
heir  CARTO  and  NavX  groups  [12]; and  Liu  et  al.  (n  =  75)  also
emonstrated  similar  results  at  7-month  follow-up  (p  =  0.06)
13].  At  present,  there  are  no  large  randomized  control  trials
omparing  the  outcomes  of  these  two  3D  approaches.
Our  PVAC  follow-up  outcomes  were  comparable  to  those
f  recent  non-randomized  studies.  Beukema  et  al.  (n  =  102)
howed  a  61%  success  with  PVAC  at  1  year  [14]. In  a  6-month
ollow-up  on  patients  with  paroxysmal  AF,  Boersma  et  al.
n  =  98)  demonstrated  an  83%  success  with  PVAC  [15], while
ieczorek  et  al.  (n  =  73)  showed  a  success  rate  of  86%  [16].
In  a  recent  randomized  study,  Bulava  et  al.  (n  =  102)  did
ot  ﬁnd  any  statistically  signiﬁcant  differences  between  the
fﬁcacy  of  PVAC  and  CARTO  at  6-month  follow  up  [17]. AF
ecurrence  was  documented  in  23  and  29%  of  patients  in  the
VAC  and  CARTO  groups,  respectively  (P  =  0.8).  Similar  to  our
tudy,  Bulava  et  al.  found  signiﬁcantly  shorter  procedural
nd  ﬂuoroscopic  times  in  the  PVAC  group  (P  <  0.0001)  [17].
LARITY-AF,  a  larger  multicentre  randomized  controlled  trial
omparing  PVAC  with  CARTO,  is  currently  in  the  enrolment
hase  [18].
R[
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Tuan  et  al.  (n  =  20)  did  not  ﬁnd  any  statistically  signiﬁ-
cant  differences  in  recurrence  rates  between  PVAC  and  NavX
(5%  vs  10%;  P  >  0.05)  [19]. However,  they  found  shorter  pro-
cedure  duration  with  PVAC  (P  <  0.001),  but  no  differences
in  ﬂuoroscopy  times.  At  present,  there  are  no  large  trials
comparing  PVAC  with  NavX.
Success  in  PVAC-guided  ablations  could  be  explained  by
the  better  lesion  integrity  created  using  circumferential
ablation  catheters  compared  to  a  point-by-point  ablation
with  3D  systems.  Better  lesion  integrity  could  reduce  the
chances  of  a  reconnection  between  trigger  foci.  Although
3D  systems  allow  precise  visualization  of  mapping  and  abla-
tion  catheters,  the  construction  of  these  complex  maps
may  require  a  steeper  learning  curve,  therefore  resulting
in  poorer  success  in  new  centres  like  ours.
Although  our  study  was  not  a  randomized  trial,  consec-
utive  patients  were  enrolled.  Six  patients  with  incomplete
procedures  were  excluded  from  this  study  to  avoid  any  unin-
tended  inﬂuence  they  may  have  had  on  outcomes.  Baseline
data  were  similar  in  the  three  groups,  so  this  is  not  expected
to  inﬂuence  the  results  of  the  study.  Despite  it  being  a  ret-
rospective  study,  we  are  conﬁdent  with  the  accuracy  of  our
data  due  to  the  standards  of  documentation  required  in  our
electronic  database.
Although  the  sample  size  of  our  study  may  be  small,  we
consider  it  to  be  sufﬁciently  large  to  represent  the  number  of
ablations  performed  at  other  new  AFA  centres.  The  number
of  cases  performed  at  our  institution  increased  substantially
throughout  and  after  the  study  period.
Data  from  12-month  follow-up,  when  available,  will
reﬂect  a  longer-term  success  of  each  technique  more  accu-
rately.  A  longer  follow-up  with  the  inclusion  of  cost-beneﬁt
analysis  would  increase  the  strength  of  future  studies.
Conclusions
Despite  being  a  new  centre  with  relatively  inexperienced
operators,  we  have  achieved  outcomes  comparable  to  those
of  established  tertiary  centres.  Although  3D  visualisation
by  CARTO  and  NavX  allows  precise  localization  of  mapping
and  ablation  catheters,  the  PVAC  group  achieved  better  out-
comes  and  lower  procedural  and  ﬂuoroscopy  times.  With  a
gentler  learning  curve,  PVAC  could  help  new  centres  to  suc-
ceed  in  AFA.  We  would  recommend  the  opening  of  more  AFA
facilities,  and  the  use  of  PVAC  in  these  centres.  We  would
also  recommend  new  centres  to  start  with  paroxysmal  AF
ablations  as  opposed  to  the  more  complex  persistent  AF
ablations.
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